Pharmacoeconomic evaluation of venlafaxine compared with citalopram in generalized anxiety disorder
- Authors:
- Jingjing Zhang
- Hongbing Xu
- Zhiqing Chen
View Affiliations
Affiliations: Department of Psychological Medicine, Shanghai First People's Hospital, Shanghai 200080, P.R. China
- Published online on: December 20, 2012 https://doi.org/10.3892/etm.2012.869
-
Pages:
840-844
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Pharmacoeconomic evaluation aims to investigate the selection and use of drugs to make patient medication efficient, safe and economical. In this study, a pharmacoeconomic evaluation was performed to assess two treatments for generalized anxiety disorder (GAD). A total of 100 outpatients with GAD were enrolled. The patients were divided into the following two groups according to treatment program: the venlafaxine group (n=50) and the citalopram group (n=50). The patients in the venlafaxine group received 75 mg of orally administered venlafaxine and 50 mg of sulpiride once a day for the first seven days and thereafter only 150 mg of venlafaxine once a day. The patients in the citalopram group received 10 mg of citalopram and 50 mg of sulpiride orally once a day for the first seven days and thereafter only 20 mg once a day. The treatment period for the two groups was three months. Follow-up was conducted at the end of weeks 2, 4 and 12 to evaluate drug efficacy, quality of life and drug side-effects. Moreover, the two groups were scored according to cost-effectiveness analysis. Using the SF-36 Scale, the quality of life score of the patients in the venlafaxine group was observed to be significantly higher compared with that of the patients in the citalopram group at the end of weeks 4 and 12 (P<0.05). The reduction rates of the Hamilton Anxiety (HAMA) scale show that the efficacy of venlafaxine was significantly better than that of citalopram by the end of week 12. The findings of this study suggest that venlafaxine is more cost-effective than citalopram in the treatment of outpatients with GAD.
View References
|
1.
|
Phillips MR, Zhang J, Shi Q, et al:
Prevalence, treatment, and associated disability of mental
disorders in four provinces in China during 2001–05: an
epidemiological survey. Lancet. 373:2041–2053. 2009.PubMed/NCBI
|
|
2.
|
Lieb R, Becker E and Altamura C: The
epidemiology of generalized anxiety disorder in Europe. Eur
Neuropsychopharmacol. 15:445–452. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Reinhold JA, Mandos LA, Rickels K and
Lohoff FW: Phamacological treatment of generalized anxiety
disorder. Expert Opin Pharmacother. 12:2457–2467. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Lenze EJ, Mulsant BH, Shear MK, et al:
Efficacy and tolerability of citalopram in the treatment of
late-life anxiety disorders: results from an 8-week randomized,
placebo-controlled trial. Am J Psychiatry. 162:146–150. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Baldwin DS and Polkinghorn C:
Evidence-based pharmacotherapy of Generalized Anxiety Disorder. Int
J Neuropsychopharmacol. 8:293–302. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Greener MJ and Guest JF: Do
antidepressants reduce the burden imposed by depression on
employers? CNS Drugs. 19:253–264. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
American Psychiatric Association: The
Diagnostic and Statistical Manual of Mental Disorders. IV Edition.
1994
|
|
8.
|
Pollack MH, Kornstein SG, Spann ME,
Crits-Christoph P, Raskin J and Russell JM: Early improvement
during duloxetine treatment of generalized anxiety disorder
predicts response and remission at endpoint. J Psychiatr Res.
42:1176–1184. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Eddama O and Coast J: A systematic review
of the use of economic evaluation in local decision-making. Health
Policy. 86:129–141. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Krystal JH, Deutsch DN and Charney DS: The
biological basis of panic disorder. J Clin Psychiatry. 57(Suppl
10): 23–31. 1996.
|
|
11.
|
Baca Baldomero E and Rubio-Terrés C:
Cost-effectiveness of venlafaxine for the treatment of depression
and anxiety. Bibliographic review. Actas Esp Psiquiatr. 34:193–201.
2006.(In Spanish).
|
